Immunosuppressive capabilities of mesenchymal stromal cells are maintained under hypoxic growth conditions and after gamma irradiation

Cytotherapy

Volumn 17, Issue 2, 2015, Pages 152-162

  Nold, Philipp ^a   Hackstein, Holger ^b   Riedlinger, Tabea ^a   Kasper, Cornelia ^c   Neumann, Anne ^c   Mernberger, Marco ^a   Fölsch, Christian ^a   Schmitt, Jan ^a   Fuchs Winkelmann, Susanne ^a   Barckhausen, Christina ^a   Killer, Madeleine ^a   Neubauer, Andreas ^a   Brendel, Cornelia ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

Author keywords

Bioreactor; Cryopreservation; Equilibration; Hypoxia; Immunosuppressive capacities; Irradiation; Mesenchymal stromal cells; MSC; Passaging; Senescence

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; BETA GALACTOSIDASE; LIPOCORTIN 5; STROMAL CELL DERIVED FACTOR 1; 5-CARBOXYFLUORESCEIN DIACETATE; CXCL12 PROTEIN, HUMAN; FLUORESCEIN DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CELL CULTURE; CELL EXPANSION; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL REGENERATION; CELL SURVIVAL; CELL TRANSPLANTATION; CONTROLLED STUDY; CRYOPRESERVATION; EX VIVO STUDY; GAMMA IRRADIATION; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOSUPPRESSIVE CAPACITY; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STROMA CELL; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REGENERATION; T LYMPHOCYTE; ADULT; ADVERSE EFFECTS; BIOSYNTHESIS; CELL HYPOXIA; CYTOLOGY; GAMMA RADIATION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; RADIATION RESPONSE;

ADULT; BETA-GALACTOSIDASE; CELL HYPOXIA; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CXCL12; CRYOPRESERVATION; FLUORESCEINS; GAMMA RAYS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; T-LYMPHOCYTES;

EID: 84922503485     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.10.004     Document Type: Article

References (53)

1. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
2. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
3. Le Blanc K., Tammik C., Rosendahl K., Zetterberg E., Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003, 31:890-896.
4. Dorronsoro A., Fernandez-Rueda J., Fechter K., Ferrin I., Salcedo J.M., Jakobsson E., et al. Human mesenchymal stromal cell-mediated immunoregulation: mechanisms of action and clinical applications. Bone Marrow Res 2013, 2013:203643.
5. Chapel A., Bertho J.M., Bensidhoum M., Fouillard L., Young R.G., Frick J., et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. JGene Med 2003, 5:1028-1038.
6. Forbes G.M., Sturm M.J., Leong R.W., Sparrow M.P., Segarajasingam D., Cummins A.G., et al. Aphase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clin Gastroenterol Hepatol 2014, 12:64-71.
7. Kebriaei P., Isola L., Bahceci E., Holland K., Rowley S., McGuirk J., et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009, 15:804-811.
8. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
9. Ringden O., Uzunel M., Rasmusson I., Remberger M., Sundberg B., Lonnies H., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
10. Weng J.Y., Du X., Geng S.X., Peng Y.W., Wang Z., Lu Z.S., et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 2010, 45:1732-1740.
11. Yamout B., Hourani R., Salti H., Barada W., El-Hajj T., Al-Kutoubi A., et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. JNeuroimmunol 2010, 227:185-189.
12. Rice C.M., Kemp K., Wilkins A., Scolding N.J. Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases. Lancet 2013, 382:1204-1213.
13. Ning H., Yang F., Jiang M., Hu L., Feng K., Zhang J., et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008, 22:593-599.
14. Martin P.J., Uberti J.P., Soiffer R.J., Klingemann H., Waller E.K., Daly A.S., et al. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase iii trial in GVHD. Biol Blood Marrow Transplant 2010, 16:S169-S170.
15. von Bonin M., Stolzel F., Goedecke A., Richter K., Wuschek N., Holig K., et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009, 43:245-251.
16. Jones M., Varella-Garcia M., Skokan M., Bryce S., Schowinsky J., Peters R., et al. Genetic stability of bone marrow-derived human mesenchymal stromal cells in the Quantum System. Cytotherapy 2013, 15:1323-1339.
17. Nekanti U., Dastidar S., Venugopal P., Totey S., Ta M. Increased proliferation and analysis of differential gene expression in human Wharton's jelly-derived mesenchymal stromal cells under hypoxia. Int J Biol Sci 2010, 6:499-512.
18. Barkholt L., Flory E., Jekerle V., Lucas-Samuel S., Ahnert P., Bisset L., et al. Risk of tumorigenicity in mesenchymal stromal cell-based therapies-bridging scientific observations and regulatory viewpoints. Cytotherapy 2013, 15:753-759.
19. Schallmoser K., Bartmann C., Rohde E., Reinisch A., Kashofer K., Stadelmeyer E., et al. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 2007, 47:1436-1446.
20. Nold P., Brendel C., Neubauer A., Bein G., Hackstein H. Good manufacturing practice-compliant animal-free expansion of human bone marrow derived mesenchymal stroma cells in a closed hollow-fiber-based bioreactor. Biochem Biophys Res Commun 2013, 430:325-330.
21. Gentleman R.C., Carey V.J., Bates D.M., Bolstad B., Dettling M., Dudoit S., et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5:R80.
22. Adhikary T., Kaddatz K., Finkernagel F., Schonbauer A., Meissner W., Scharfe M., et al. Genomewide analyses define different modes of transcriptional regulation by peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). PLoS One 2011, 6:e16344.
23. Kim M.N., Lee K.E., Hong J.Y., Heo W.I., Kim K.W., Kim K.E., et al. Involvement of the MAPK and PI3K pathways in chitinase 3-like 1-regulated hyperoxia-induced airway epithelial cell death. Biochem Biophys Res Commun 2012, 421:790-796.
24. Kryczek I., Lange A., Mottram P., Alvarez X., Cheng P., Hogan M., et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005, 65:465-472.
25. Debacq-Chainiaux F., Erusalimsky J.D., Campisi J., Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and invivo. Nat Protocols 2009, 4:1798-1806.
26. Gesetz zur Regelung des Transfusionswesens (Transfusionsgesetz) [Law regulating the transfusion system]. Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). Gesamtnovelle 2005 mit Richtlinienanpassung 2010 [Guidelines for the collection of blood and blood components and the use of blood products (Hemotherapy). 2005 Amendment to the 2010 directive]. Köln: deutscher Ärzte-Verlag; 2010, p. 41-43.
27. Francois M., Copland I.B., Yuan S., Romieu-Mourez R., Waller E.K., Galipeau J. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing. Cytotherapy 2012, 14:147-152.
28. Crisostomo P.R., Wang M., Wairiuko G.M., Morrell E.D., Terrell A.M., Seshadri P., et al. High passage number of stem cells adversely affects stem cell activation and myocardial protection. Shock 2006, 26:575-580.
29. von Bahr L., Sundberg B., Lonnies L., Sander B., Karbach H., Hagglund H., et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 2012, 18:557-564.
30. Harrison J.S., Rameshwar P., Chang V., Bandari P. Oxygen saturation in the bone marrow of healthy volunteers. Blood 2002, 99:394.
31. Radak Z., Zhao Z., Goto S., Koltai E. Age-associated neurodegeneration and oxidative damage to lipids, proteins and DNA. Mol Aspects Med 2011, 32:305-315.
32. Lonne M., Lavrentieva A., Walter J.G., Kasper C. Analysis of oxygen-dependent cytokine expression in human mesenchymal stem cells derived from umbilical cord. Cell Tissue Res 2013, 353:117-122.
33. Gorgens S.W., Eckardt K., Elsen M., Tennagels N., Eckel J. Chitinase-3-like protein 1 protects skeletal muscle from TNFalpha-induced inflammation and insulin resistance. Biochem J 2014, 459:479-488.
34. Schellenberg A., Lin Q., Schuler H., Koch C.M., Joussen S., Denecke B., et al. Replicative senescence of mesenchymal stem cells causes DNA-methylation changes which correlate with repressive histone marks. Aging 2011, 3:873-888.
35. Kretlow J.D., Jin Y.Q., Liu W., Zhang W.J., Hong T.H., Zhou G., et al. Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells. BMC Cell Biol 2008, 9:60.
36. Wall M.E., Bernacki S.H., Loboa E.G. Effects of serial passaging on the adipogenic and osteogenic differentiation potential of adipose-derived human mesenchymal stem cells. Tissue Eng 2007, 13:1291-1298.
37. Kebriaei P., Robinson S. Treatment of graft-versus-host-disease with mesenchymal stromal cells. Cytotherapy 2011, 13:262-268.
38. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
39. Moll G., Alm J.J., Davies L.C., von Bahr L., Heldring N., Stenbeck-Funke L., et al. Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties ?. Stem Cells 2014, 32:2430-2442.
40. Chow D.C., Wenning L.A., Miller W.M., Papoutsakis E.T. Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models. Biophys J 2001, 81:685-696.
41. Lavrentieva A., Majore I., Kasper C., Hass R. Effects of hypoxic culture conditions on umbilical cord-derived human mesenchymal stem cells. Cell Commun Signal 2010, 8:18.
42. McGuirk J.P., Weiss M.L. Promising cellular therapeutics for prevention or management of graft-versus-host disease (areview). Placenta 2011, 32(Suppl. 4):S304-S310.
43. Estrada J.C., Albo C., Benguria A., Dopazo A., Lopez-Romero P., Carrera-Quintanar L., et al. Culture of human mesenchymal stem cells at low oxygen tension improves growth and genetic stability by activating glycolysis. Cell Death Differ 2012, 19:743-755.
44. Hung S.C., Pochampally R.R., Hsu S.C., Sanchez C., Chen S.C., Spees J., et al. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment invivo. PLoS One 2007, 2:e416.
45. Tsai C.C., Chen Y.J., Yew T.L., Chen L.L., Wang J.Y., Chiu C.H., et al. Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood 2011, 117:459-469.
46. Zafranskaya M.M., Nizheharodova D.B., Yurkevich M.Y., Lamouskaya N.V., Motuzova Y.M., Bagatka S.S., et al. Invitro assessment of mesenchymal stem cells immunosuppressive potential in multiple sclerosis patients. Immunol Lett 2013, 149:9-18.
47. Alessio N., Bohn W., Rauchberger V., Rizzolio F., Cipollaro M., Rosemann M., et al. Silencing of RB1 but not of RB2/P130 induces cellular senescence and impairs the differentiation potential of human mesenchymal stem cells. Cell Mol Life Sci 2013, 70:1637-1651.
48. Despars G., Carbonneau C.L., Bardeau P., Coutu D.L., Beausejour C.M. Loss of the osteogenic differentiation potential during senescence is limited to bone progenitor cells and is dependent on p53. PLoS One 2013, 8:e73206.
49. von Bahr L., Batsis I., Moll G., Hagg M., Szakos A., Sundberg B., et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells 2012, 30:1575-1578.
50. Choumerianou D.M., Dimitriou H., Perdikogianni C., Martimianaki G., Riminucci M., Kalmanti M. Study of oncogenic transformation in exvivo expanded mesenchymal cells, from paediatric bone marrow. Cell Prolif 2008, 41:909-922.
51. Rojewski M.T., Fekete N., Baila S., Nguyen K., Furst D., Antwiler D., et al. GMP-compliant isolation and expansion of bone marrow-derived MSCs in the closed, automated device quantum cell expansion system. Cell Transplant 2013, 22:1981-2000.
52. de Andrade A.V., Riewaldt J., Wehner R., Schmitz M., Odendahl M., Bornhauser M., et al. Gamma irradiation preserves immunosuppressive potential and inhibits clonogenic capacity of human bone marrow-derived mesenchymal stromal cells. JCell Mol Med 2014, 18:1184-1193.
53. Fekete N, Erle A, Amann EM, Furst D, Rojewski MT, Langonne A, etal. Effect of high-dose irradiation on human bone-marrow-derived mesenchymal stromal cells [published online ahead of print July 22, 2014]. Tissue Eng C Methods.